An emerging antiarrhythmic target

Late sodium current

T. Banyasz, N. Szentandrássy, J. Magyar, Z. Szabo, P. P. Nánási, Ye Chen-Izu, Leighton T Izu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The cardiac late sodium current (INa,L) has been in the focus of research in the recent decade. The first reports on the sustained component of voltage activated sodium current date back to the seventies, but early studies interpreted this tiny current as a product of a few channels that fail to inactivate, having neither physiologic nor pathologic implications. Recently, the cardiac INa,L has emerged as a potentially major arrhythmogenic mechanism in various heart diseases, attracting the attention of clinicians and researchers. Research activity on INa,L has exponentially increased since Ranolazine, an FDA-approved antianginal drug was shown to successfully suppress cardiac arrhythmias by inhibiting INa,L. This review aims to summarize and discuss a series of papers focusing on the cardiac late sodium current and its regulation under physiological and pathological conditions. We will discuss critical evidences implicating INa,L as a potential target for treating myocardial dysfunction and cardiac arrhythmias.

Original languageEnglish (US)
Pages (from-to)1073-1090
Number of pages18
JournalCurrent Pharmaceutical Design
Volume21
Issue number8
StatePublished - Jan 1 2015

Fingerprint

Sodium
Cardiac Arrhythmias
Research
Heart Diseases
Research Personnel
Pharmaceutical Preparations
Ranolazine

Keywords

  • Arrhythmias
  • Cardiac sodium channel
  • Late sodium current

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Banyasz, T., Szentandrássy, N., Magyar, J., Szabo, Z., Nánási, P. P., Chen-Izu, Y., & Izu, L. T. (2015). An emerging antiarrhythmic target: Late sodium current. Current Pharmaceutical Design, 21(8), 1073-1090.

An emerging antiarrhythmic target : Late sodium current. / Banyasz, T.; Szentandrássy, N.; Magyar, J.; Szabo, Z.; Nánási, P. P.; Chen-Izu, Ye; Izu, Leighton T.

In: Current Pharmaceutical Design, Vol. 21, No. 8, 01.01.2015, p. 1073-1090.

Research output: Contribution to journalArticle

Banyasz, T, Szentandrássy, N, Magyar, J, Szabo, Z, Nánási, PP, Chen-Izu, Y & Izu, LT 2015, 'An emerging antiarrhythmic target: Late sodium current', Current Pharmaceutical Design, vol. 21, no. 8, pp. 1073-1090.
Banyasz T, Szentandrássy N, Magyar J, Szabo Z, Nánási PP, Chen-Izu Y et al. An emerging antiarrhythmic target: Late sodium current. Current Pharmaceutical Design. 2015 Jan 1;21(8):1073-1090.
Banyasz, T. ; Szentandrássy, N. ; Magyar, J. ; Szabo, Z. ; Nánási, P. P. ; Chen-Izu, Ye ; Izu, Leighton T. / An emerging antiarrhythmic target : Late sodium current. In: Current Pharmaceutical Design. 2015 ; Vol. 21, No. 8. pp. 1073-1090.
@article{72a04c797af047b0bf78d22a7970318a,
title = "An emerging antiarrhythmic target: Late sodium current",
abstract = "The cardiac late sodium current (INa,L) has been in the focus of research in the recent decade. The first reports on the sustained component of voltage activated sodium current date back to the seventies, but early studies interpreted this tiny current as a product of a few channels that fail to inactivate, having neither physiologic nor pathologic implications. Recently, the cardiac INa,L has emerged as a potentially major arrhythmogenic mechanism in various heart diseases, attracting the attention of clinicians and researchers. Research activity on INa,L has exponentially increased since Ranolazine, an FDA-approved antianginal drug was shown to successfully suppress cardiac arrhythmias by inhibiting INa,L. This review aims to summarize and discuss a series of papers focusing on the cardiac late sodium current and its regulation under physiological and pathological conditions. We will discuss critical evidences implicating INa,L as a potential target for treating myocardial dysfunction and cardiac arrhythmias.",
keywords = "Arrhythmias, Cardiac sodium channel, Late sodium current",
author = "T. Banyasz and N. Szentandr{\'a}ssy and J. Magyar and Z. Szabo and N{\'a}n{\'a}si, {P. P.} and Ye Chen-Izu and Izu, {Leighton T}",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "21",
pages = "1073--1090",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - An emerging antiarrhythmic target

T2 - Late sodium current

AU - Banyasz, T.

AU - Szentandrássy, N.

AU - Magyar, J.

AU - Szabo, Z.

AU - Nánási, P. P.

AU - Chen-Izu, Ye

AU - Izu, Leighton T

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The cardiac late sodium current (INa,L) has been in the focus of research in the recent decade. The first reports on the sustained component of voltage activated sodium current date back to the seventies, but early studies interpreted this tiny current as a product of a few channels that fail to inactivate, having neither physiologic nor pathologic implications. Recently, the cardiac INa,L has emerged as a potentially major arrhythmogenic mechanism in various heart diseases, attracting the attention of clinicians and researchers. Research activity on INa,L has exponentially increased since Ranolazine, an FDA-approved antianginal drug was shown to successfully suppress cardiac arrhythmias by inhibiting INa,L. This review aims to summarize and discuss a series of papers focusing on the cardiac late sodium current and its regulation under physiological and pathological conditions. We will discuss critical evidences implicating INa,L as a potential target for treating myocardial dysfunction and cardiac arrhythmias.

AB - The cardiac late sodium current (INa,L) has been in the focus of research in the recent decade. The first reports on the sustained component of voltage activated sodium current date back to the seventies, but early studies interpreted this tiny current as a product of a few channels that fail to inactivate, having neither physiologic nor pathologic implications. Recently, the cardiac INa,L has emerged as a potentially major arrhythmogenic mechanism in various heart diseases, attracting the attention of clinicians and researchers. Research activity on INa,L has exponentially increased since Ranolazine, an FDA-approved antianginal drug was shown to successfully suppress cardiac arrhythmias by inhibiting INa,L. This review aims to summarize and discuss a series of papers focusing on the cardiac late sodium current and its regulation under physiological and pathological conditions. We will discuss critical evidences implicating INa,L as a potential target for treating myocardial dysfunction and cardiac arrhythmias.

KW - Arrhythmias

KW - Cardiac sodium channel

KW - Late sodium current

UR - http://www.scopus.com/inward/record.url?scp=84925864654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925864654&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 1073

EP - 1090

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 8

ER -